Growth Metrics

Innoviva (INVA) Income from Continuing Operations (2010 - 2026)

Innoviva posted quarterly Income from Continuing Operations of 186563000.0 for Q1 2026, up 500.44% year-on-year from 31070824.82 in Q1 2025, and up 1449.66% on a QoQ basis from 13823000.0 in Q4 2025.

Innoviva (INVA) has 17 years of Income from Continuing Operations data on file, last reported at 186563000.0 in Q1 2026.

  • For the quarter ending Q1 2026, Income from Continuing Operations rose 500.44% year-over-year to 186563000.0; the trailing twelve-month figure through Mar 2026 stood at 326345000.0 (up 460.2% YoY), and the FY2025 full-year result was 271363000.0, up 2424.54% from the prior year.
  • Income from Continuing Operations for Q1 2026 stood at 186563000.0, up from 13823000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 229347000.0 in Q3 2022 and bottomed at 46589000.0 in Q1 2025.
  • The 5-year median for Income from Continuing Operations is 21395000.0 (2022), against an average of 38951705.88.
  • The widest annual swing landed in 2024, when Income from Continuing Operations plunged 2757.85%; it then soared 7312.78% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 10328000.0 in 2022, then surged by 36.31% to 6578000.0 in 2023, then plunged by 60.22% to 10539000.0 in 2024, then tumbled by 31.16% to 13823000.0 in 2025, then surged by 1449.66% to 186563000.0 in 2026.
  • The last three Income from Continuing Operations figures came in at 186563000.0 (Q1 2026), 13823000.0 (Q4 2025), and 89917000.0 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -2.99 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -8.40 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -14.46 Mn
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 1.03 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - -3.40 Mn
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 727.20 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 205.99 Mn
10 Innoviva 1.60 Bn 992.84 Mn 75.83 Mn 186.56 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 186.56 Mn
Dec 31, 2025 -13.82 Mn
Sep 30, 2025 89.92 Mn
Jun 30, 2025 63.69 Mn
Mar 31, 2025 -46.59 Mn
Dec 31, 2024 -10.54 Mn
Sep 30, 2024 1.21 Mn
Jun 30, 2024 -34.69 Mn
Mar 31, 2024 36.52 Mn
Dec 31, 2023 -6.58 Mn
Sep 30, 2023 82.05 Mn
Jun 30, 2023 1.31 Mn
Mar 31, 2023 34.87 Mn
Dec 31, 2022 -10.33 Mn
Sep 30, 2022 229.35 Mn
Jun 30, 2022 21.40 Mn
Mar 31, 2022 37.86 Mn
Dec 31, 2021 -6.05 Mn
Sep 30, 2021 102.68 Mn
Jun 30, 2021 110.88 Mn
Mar 31, 2021 109.73 Mn
Dec 31, 2020 75.02 Mn
Sep 30, 2020 41.59 Mn
Jun 30, 2020 98.22 Mn
Mar 31, 2020 78.98 Mn
Dec 31, 2019 57.86 Mn
Sep 30, 2019 47.05 Mn
Jun 30, 2019 46.06 Mn
Mar 31, 2019 40.03 Mn
Dec 31, 2018 269.22 Mn
Sep 30, 2018 50.17 Mn
Jun 30, 2018 56.62 Mn
Mar 31, 2018 30.33 Mn
Dec 31, 2017 30.31 Mn
Sep 30, 2017 34.03 Mn
Jun 30, 2017 35.93 Mn
Mar 31, 2017 16.80 Mn
Dec 31, 2016 24.83 Mn
Sep 30, 2016 14.98 Mn
Jun 30, 2016 12.88 Mn
Mar 31, 2016 4.47 Mn
Dec 31, 2015 4.30 Mn
Sep 30, 2015 -4.58 Mn
Jun 30, 2015 -7.81 Mn
Mar 31, 2015 -10.67 Mn
Dec 31, 2014 -15.93 Mn
Sep 30, 2014 -21.27 Mn
Jun 30, 2014 -20.15 Mn
Mar 31, 2014 -16.18 Mn
Dec 31, 2013 -8.89 Mn
Sep 30, 2013 -9.45 Mn
Jun 30, 2013 -1.54 Mn
Mar 31, 2013 -35.94 Mn
Dec 31, 2012 -43.47 Mn
Sep 30, 2012 -34.69 Mn
Jun 30, 2012 -37.12 Mn
Mar 31, 2012 84.59 Mn
Dec 31, 2011 -37.01 Mn
Sep 30, 2011 -30.63 Mn
Jun 30, 2011 -25.05 Mn
Mar 31, 2011 -22.81 Mn
Dec 31, 2010 -19.44 Mn
Sep 30, 2010 -21.22 Mn
Jun 30, 2010 -20.81 Mn